STOCK TITAN

Aldeyra Therapeu - ALDX STOCK NEWS

Welcome to our dedicated page for Aldeyra Therapeu news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeu stock.

Aldeyra Therapeutics (ALDX) is a clinical-stage biotechnology company developing innovative therapies targeting diseases mediated by toxic aldehydes, with active programs in ocular inflammation and systemic immune disorders. This page provides investors and industry professionals with comprehensive access to Aldeyra's official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.

Key resources include real-time updates on product candidates like reproxalap for dry eye disease, filings with regulatory agencies, and research collaborations. Users gain a centralized hub to track the company's progress in addressing conditions such as noninfectious anterior uveitis and metabolic disorders through its novel aldehyde sequestration platform.

Regular updates cover Phase clinical results, FDA communications, intellectual property developments, and scientific presentations. The curated news feed enables efficient monitoring of Aldeyra's pipeline advancements and market positioning within the precision medicine landscape.

Bookmark this page for direct access to verified ALDX disclosures and analysis essential for evaluating the company's therapeutic innovations and investment potential.

Rhea-AI Summary
Aldeyra Therapeutics, Inc. (ALDX) announced that its CEO will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The virtual conference will take place on February 13-14, 2024. The conversation will be available for live webcast and archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.05%
Tags
conferences
-
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announces advancement of its RASP modulator platform, including the expected submission to the FDA of a proposed expansion of the Phase 2 clinical trial of the investigational RASP modulator ADX-629 in Sjögren-Larsson Syndrome to include pediatric patients, initiation of a Phase 2 clinical trial of ADX-629 in moderate alcoholic hepatitis, and submission of IND applications for ADX-246 and ADX-248 for clinical trials in atopic dermatitis and dry age-related macular degeneration patients, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced positive top-line results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in patients with atopic dermatitis. The trial demonstrated statistically significant improvement in EASI, IGA, HAM-D, and POEM scores, with complete resolution of affected body surface area observed in one patient. The company plans to advance ADX-246, a next-generation investigational RASP modulator, to Phase 1/2 clinical testing in healthy volunteers and atopic dermatitis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.58%
Tags
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced a webcast and conference call to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.58%
Tags
-
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (ALDX) receives a Complete Response Letter from the FDA for reproxalap, an investigational drug candidate for dry eye disease. The FDA states that the NDA did not demonstrate efficacy in treating ocular symptoms associated with dry eyes, requiring an additional trial. Aldeyra submitted a Special Protocol Assessment for a dry eye disease chamber crossover clinical trial, with top-line results anticipated in the first half of 2024. The potential NDA resubmission is also expected in the first half of 2024. Aldeyra plans to extend its cash runway into late 2025, with $143 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
-
Rhea-AI Summary
Aldeyra Therapeutics has entered into an exclusive option agreement with AbbVie Inc. The agreement grants AbbVie the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the U.S. and an exclusive license to do the same outside the U.S. Aldeyra will receive a $1 million non-refundable option fee and a $100 million upfront payment if AbbVie exercises the option. Aldeyra could also receive up to $300 million in regulatory and commercial milestone payments. The terms of the license agreement include profit and loss sharing between Aldeyra and AbbVie, with a 60% split for AbbVie and 40% for Aldeyra in the U.S. market. Aldeyra would also be eligible for tiered royalties on net sales of reproxalap outside the U.S. AbbVie will have the right of first negotiation for compounds owned or controlled by Aldeyra in the field of ophthalmology relating to treating conditions of the ocular surface.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.54%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
conferences
-
Rhea-AI Summary
Aldeyra Therapeutics announces positive results from Phase 2 clinical trial of ADX-2191 for retinitis pigmentosa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
-
Aldeyra Therapeu

Nasdaq:ALDX

ALDX Rankings

ALDX Stock Data

130.76M
53.38M
2.44%
63.08%
6.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
LEXINGTON